{"schema_version":"secwatch.filing_event.v1","accession":"0000721371-24-000005","form_type":"8-K","ticker":"CAH","cik":"0000721371","company_name":"CARDINAL HEALTH INC","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.752316+00:00","generated_at":"2026-06-07T01:43:41.692636+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cardinal Health raises FY2024 non-GAAP EPS guidance to high end of $6.75–$7.00 on strong cash flow and $250M ASR","bullets":["Updated FY2024 non-GAAP diluted EPS guidance to high end of $6.75–$7.00.","Executed $250M accelerated share repurchase in Q2; cash flow strength drove favorability.","Completed review of at-Home Solutions ($2.6B rev) and OptiFreight Logistics ($250M rev); will invest and develop them.","New segment structure effective Jan 1, 2024: Pharmaceutical & Specialty Solutions, GMPD, and Other.","Q2 Medical segment profit expected consistent with Q1, but on track for FY26 target of $650M."],"urls":{"canonical":"https://secwatch.observer/filing/0000721371-24-000005","json":"https://secwatch.observer/filing/0000721371-24-000005.json","markdown":"https://secwatch.observer/filing/0000721371-24-000005.md","text":"https://secwatch.observer/filing/0000721371-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000005/0000721371-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000005/cah-20240109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:43:41.692636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b23c2dbadd0abdbf50b002f2adb414a6df51789b","claim":"CARDINAL HEALTH INC reported fiscal year 2024 results: EPS high end of $6.75 to $7.00 range. Guidance raised.","evidence_excerpt":"Updated fiscal 2024 non-GAAP diluted EPS guidance to high end of $6.75 to $7.00 range","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000005/0000721371-24-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"EPS","value":"high end of $6.75 to $7.00 range"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}